$GH Income Statement | Understand Stock

$GH

$173.25 +$4.17 (2.47%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Precision oncology testing
Development services and other
Revenue
Costs and operating expenses:
Cost of precision oncology testing
Cost of development services and other
Cost of revenue
Research and development expense
Sales and marketing expense
General and administrative expense
Other operating expense
Total costs and operating expenses
Loss from operations
Interest income
Interest expense
Other income (expense), net
Fair value adjustments of noncontrolling interest liability
Loss before (benefit from) provision for income taxes
(Benefit from) provision for income taxes
Adjustment of redeemable noncontrolling interest
Net loss attributable to Guardant Health, Inc. common stockholders - basic
Net loss
Net loss per share, basic (in usd per share)
Net loss per share, diluted (in usd per share)
Weighted-average shares used in computing net loss per share, basic (in shares)
Weighted-average shares used in computing net loss per share, diluted (in shares)

Comments